Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Research & Development (2016 - 2026)

Perspective Therapeutics' Research & Development history spans 17 years, with the latest figure at $21.4 million for Q1 2026.

  • On a quarterly basis, Research & Development rose 49.12% to $21.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $91.3 million, a 88.08% increase, with the full-year FY2025 number at $84.2 million, up 102.26% from a year prior.
  • Research & Development hit $21.4 million in Q1 2026 for Perspective Therapeutics, down from $32.9 million in the prior quarter.
  • Over the last five years, Research & Development for CATX hit a ceiling of $32.9 million in Q4 2025 and a floor of $468000.0 in Q4 2022.
  • Historically, Research & Development has averaged $10.1 million across 5 years, with a median of $7.5 million in 2024.
  • Biggest five-year swings in Research & Development: decreased 12.52% in 2022 and later soared 1412.82% in 2023.
  • Tracing CATX's Research & Development over 5 years: stood at $468000.0 in 2022, then soared by 1412.82% to $7.1 million in 2023, then skyrocketed by 81.96% to $12.9 million in 2024, then soared by 155.56% to $32.9 million in 2025, then tumbled by 35.09% to $21.4 million in 2026.
  • Business Quant data shows Research & Development for CATX at $21.4 million in Q1 2026, $32.9 million in Q4 2025, and $20.3 million in Q3 2025.